Loading patent…
AssigneeArcutis Biotherapeutics, Inc.
InventorsDavid Reuben BERK, Patrick Eugene BURNETT, Saori KATO, David W. OSBORNE
Estimating the term…
The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.
A method of treating a fungal infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of roflumilast or a pharmaceutically acceptable salt thereof, wherein the fungal infection is caused by Malassezia spp.
A method for reducing facial redness or inflammation due to a Malassezia infection, treatment of a Malassezia infection and/or Malassezia hypersensitivity, comprising topically administering an effective amount of roflumilast to a patient in need of such treatment.
A method of treating a fungal infection, fungal overgrowth and/or hypersensitivity to Malassezia spp in a subject in need thereof, comprising topically administering to the subject a therapeutically effective amount of roflumilast or a pharmaceutically acceptable salt thereof, wherein the fungal infection or overgrowth is caused by Malassezia spp.
A method for reducing facial redness and inflammation caused by treatment of moderate to severe atopic dermatitis, comprising topically administering to a subject in need of such treatment, a therapeutically effective amount of roflumilast or a pharmaceutically acceptable salt thereof, wherein said facial redness and inflammation is caused by a Malassezia spp infection.
Dependencies are inferred from the claim text.